ACOR - Acorda Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
17.68
+0.13 (+0.74%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close17.55
Open17.75
Bid15.80 x 1000
Ask19.00 x 900
Day's Range17.26 - 17.77
52 Week Range15.60 - 36.35
Volume491,644
Avg. Volume709,179
Market Cap839.514M
Beta (3Y Monthly)2.35
PE Ratio (TTM)N/A
EPS (TTM)-3.42
Earnings DateOct 29, 2018 - Nov 2, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.22
Trade prices are not sourced from all markets
  • Benzinga16 hours ago

    The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs

    Here are a few catalysts that can dictate the directional moves of biotech stocks in the upcoming week: Conferences European Society For Medical Oncology, or ESMO, 2018 Congress – Oct. 19-23, in Munich, ...

  • Who Is Eyeing Acorda Therapeutics?
    Market Realist6 days ago

    Who Is Eyeing Acorda Therapeutics?

    In September, the FDA extended Acorda Therapeutics’ (ACOR) PDUFA (Prescription Drug User Fee Act) action date for its NDA (New Drug Application) of Inbrija from October 5 to January 5, 2019. The FDA extended Acorda Therapeutics’ PDUFA action date after the submission of additional information that the FDA requested.

  • See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
    Markit7 days ago

    See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.

    Acorda Therapeutics Inc NASDAQ/NGS:ACOR

  • Benzinga7 days ago

    The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs

    As we step into the final quarter of 2018, biotech stocks have recorded double-digit gains for the year-to-date period. Will the run up continue? Stay tuned to the following events of the upcoming week. ...

  • Analysts Remain Bullish on Intercept Pharmaceuticals
    Market Realist12 days ago

    Analysts Remain Bullish on Intercept Pharmaceuticals

    In October, of the 17 analysts covering Intercept Pharmaceuticals (ICPT), eight have given the stock “buy” or higher ratings, and eight have given it “hold” ratings. One analyst has given Intercept a “sell.” 

  • Mylan’s Recently Launched Generic Version of Ampyra
    Market Realist12 days ago

    Mylan’s Recently Launched Generic Version of Ampyra

    On September 21, Mylan (MYL) launched its authorized generic version of Acorda Therapeutics’ (ACOR) Ampyra (dalfampridine), which is used for improvement in walking for adults who have multiple sclerosis. Mylan’s dalfampridine extended-release tablets are available in 10 mg tablets, similar to Acorda’s Ampyra. On September 21, MYL stock rose ~2.2% before closing up ~0.67% over the previous day’s closing price.

  • Business Wire13 days ago

    Acorda to Present Data for INBRIJA™ (levodopa inhalation powder) at International Congress of Parkinson’s Disease and Movement Disorders

    Acorda Therapeutics, Inc. (ACOR) will present a new post-hoc efficacy analysis from SPAN-PD, the pivotal Phase 3 trial of INBRIJA, at the upcoming International Congress of Parkinson’s Disease and Movement Disorders® taking place October 5-9, 2018 in Hong Kong. INBRIJA is an investigational inhaled levodopa treatment for symptoms of OFF periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen. The INBRIJA poster, Efficacy of CVT-301 (levodopa inhalation powder) for treatment of OFF periods in Parkinson’s disease (Abstract #369), will be presented on Saturday, October 6, 2018, as part of the Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment poster session from 1:45 PM to 3:15 PM. Posters will be available for viewing from 9:00 AM to 5:00 PM.

  • See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
    Markit25 days ago

    See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.

    Acorda Therapeutics Inc NASDAQ/NGS:ACOR

  • See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
    Markit28 days ago

    See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.

    Acorda Therapeutics Inc NASDAQ/NGS:ACOR

  • Acorda (ACOR) Stock Dips, FDA Delays Decision on Inbrija
    Zackslast month

    Acorda (ACOR) Stock Dips, FDA Delays Decision on Inbrija

    The FDA defers decision by three months regarding the NDA of Acorda's (ACOR) Parkinson's disease candidate Inbrija for the treatment of OFF periods.

  • Associated Presslast month

    Qualcomm and Tailored Brands rise; Kroger stumbles

    Stocks that moved substantially or traded heavily Thursday: Progenics Pharmaceuticals Inc., down $1.30 to $6 The company reported disappointing results from a study of an imaging compound used in prostate ...

  • Motley Foollast month

    Here's Why Acorda Therapeutics Is Falling by Double Digits Today

    Shares retreated after the company provided Wall Street with an updated regulatory timeline. Here's what investors need to know.

  • MarketWatchlast month

    Acorda shares slide 19% premarket after FDA delays review of Parkinson's treatment

    Shares of Acorda Therapeutics Inc. slid 19% Thursday, after the company said the U.S. Food and Drugs Administration has extended the review period for a treatment for symptoms of Parkinson Disease. The extension comes after Acorda submitted additional information on its Inbrija, an inhaled levodopa therapy that aims to reduce off times, or the periods when standard levodopa treatment stops working. The FDA determined that the additional information constituted a major amendment that would take longer to review. The regulator moved the review date back to Jan. 5, 2019 from Oct. 5, 2018. Parkinson's is a progressive neurodegenerative disorder that affects about 1 million people in the U.S. and 1.2 million people in Europe. Acorda shares have fallen 13.8% in 2018, while the S&P 500 has gained 8.1%.

  • Business Wirelast month

    Acorda Announces FDA Extends INBRIJA NDA Review Period

    Acorda Therapeutics, Inc. (ACOR) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) of INBRIJA™ (levodopa inhalation powder) from October 5, 2018 to January 5, 2019. This extension is related to recent submissions Acorda made in response to requests from FDA for additional information on chemistry, manufacturing and controls (CMC). FDA determined that these submissions constitute a major amendment and will take additional time to review.

  • Acorda Gets Unfavorable Court Ruling for Ampyra, Stock Down
    Zackslast month

    Acorda Gets Unfavorable Court Ruling for Ampyra, Stock Down

    Acorda Therapeutics' (ACOR) stock slumps after a Federal Circuit Court rules against its appeal to protect patents pertaining to its key multiple sclerosis drug, Ampyra

  • Are Options Traders Betting on a Big Move in Acorda (ACOR) Stock?
    Zackslast month

    Are Options Traders Betting on a Big Move in Acorda (ACOR) Stock?

    Investors need to pay close attention to Acorda (ACOR) stock based on the movements in the options market lately.

  • ACCESSWIRElast month

    Today’s Research Reports on Stocks to Watch: Acorda Therapeutics and Avid Bioservices

    NEW YORK, NY / ACCESSWIRE / September 11, 2018 / Acorda shares were deep in the red after a disappointing court ruling on Monday. A U.S. District Court of Appeals has held up a lower court ruling invalidating key patents on Ampyra, the company’s multiple sclerosis drug that accounts for most of its sales. Shares of Avid Bioservices traded fairly flat during the day but soared in after-hours extended trading after reporting stellar first quarter financial results.

  • Why Brown-Forman, Acorda Therapeutics, and Energy XXI Gulf Coast Slumped Today
    Motley Foollast month

    Why Brown-Forman, Acorda Therapeutics, and Energy XXI Gulf Coast Slumped Today

    Find out which of these companies lost the most ground.

  • What's Behind Acorda Therapeutics Crashing 24.5% Today
    Motley Foollast month

    What's Behind Acorda Therapeutics Crashing 24.5% Today

    The company could face stiff competition following an unfavorable ruling by an appeals court.

  • MarketWatchlast month

    Acorda's stock plunges after disappointing ruling regarding patents for MS treatment

    Shares of Acorda Therapeutics Inc. plunged 21% toward an 8-month low in midday trade Monday, after a disappointing ruling a federal appeals court on patents pertaining to its multiple sclerosis treatment, Ampyra. The company said the U.S. Court of Appeals upheld by a 2-to-1 vote the U.S. District Court of Delaware's decision to invalidate four Ampyra patents. That validates the District Court's ruling on March 31, 2017, which invalidated patents pertaining to Ampyra extended release tablets. Acorda said it was reviewing the decision and its options, including a further appeal. "We are disappointed by the Court's decision, as we continue to believe that our AMPYRA patents reflected true invention and were valid," Chief Executive Ron Cohen said in a statement. "Following the Court's original decision in 2017, we prepared a contingency plan that we could face generic competition, implementing a comprehensive corporate restructuring and bolstering our balance sheet." Despite the stock's sharp selloff, it has gained 1.2% year to date, while the S&P 500 has tacked on 7.7%.

  • Business Wirelast month

    U.S. Court of Appeals for the Federal Circuit Upholds District Court’s Decision to Invalidate AMPYRA® (dalfampridine) Patents

    Acorda Therapeutics, Inc. (ACOR) today announced that the United States Court of Appeals for the Federal Circuit, by a 2-1 vote, has upheld the United States District Court for the District of Delaware’s decision to invalidate four AMPYRA patents. This decision affirms the District Court’s ruling on March 31, 2017 invalidating U.S. Patent Nos. 8,663,685 (the ‘685 patent), 8,007,826 (the ‘826 patent), 8,440,703 (the ‘703 patent), and 8,354,437 (the ‘437 patent) pertaining to AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg. Acorda’s U.S. Patent No. 5,540,938 (the ‘938 patent), previously upheld by the District Court, expired on July 30, 2018.

  • See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.

    Acorda Therapeutics Inc NASDAQ/NGS:ACOR

  • GlobeNewswire2 months ago

    Market Trends Toward New Normal in Acorda Therapeutics, Red Robin Gourmet Burgers, Plug Power, Group 1 Automotive, Shutterfly, and National Fuel Gas — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Acorda ...

  • Business Wire2 months ago

    Acorda Announces Management Transitions

    Acorda Therapeutics, Inc. (ACOR) today announced that Rick Batycky, Ph.D., Chief Technology Officer, will be leaving Acorda as of August 20, 2018 to take a position as the CEO of a private, venture-backed biotechnology company. David Lawrence, Acorda’s Chief of Business Operations, will assume responsibility for the company’s Chelsea, MA manufacturing facility, which produces INBRIJA™ (levodopa inhalation powder), as well as for the external manufacturing of AMPYRA® (dalfampridine). Burkhard Blank, M.D., Acorda’s Chief Medical Officer, will assume responsibility for Acorda’s Pharmaceutical Development and Technical Operations teams.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ACOR earnings conference call or presentation 2-Aug-18 12:30pm GMT

    Q2 2018 Acorda Therapeutics Inc Earnings Call